12:00 AM
 | 
Mar 08, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ares-Serono regulatory update

The company received a letter from the FDA stating that its Rebif interferon beta-1a may not be approved for marketing...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >